Biogen Idec, Abbott release Select Phase 2b RRMS drug trial results
The results of the trial demonstrated that the DAC HYP showed reduction in annualized relapse rate by 54% when administered subcutaneously once every four weeks in 150mg dose
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.